Sign In
Buy PBLA
$0.0010
+0 (+0%)
At Close: Jun 03, 2026
Leap Therapeutics (NASDAQ:LPTX) vs. Panbela Therapeutics (OTCMKTS:PBLA) Head-To-Head Analysis
01:14am, Tuesday, 03'rd Mar 2026
Leap Therapeutics (NASDAQ: LPTX - Get Free Report) and Panbela Therapeutics (OTCMKTS:PBLA - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will com
Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript
06:33pm, Thursday, 14'th Nov 2024
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Jennifer Simpson - CEO Sue Horvath - CFO Conference Call Participants Jonatha
Panbela Provides Business Update and Reports Q3 2024 Financial Results
04:10pm, Thursday, 14'th Nov 2024
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet
Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript
07:39pm, Tuesday, 13'th Aug 2024
Panbela Therapeutics, Inc. (OTCQB:PBLA) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants James Carbonara - Hayden, IR Jennifer Simpson - President and Chief Executive O
Panbela Provides Business Update and Reports Q2 2024 Financial Results
04:10pm, Tuesday, 13'th Aug 2024
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
04:15pm, Tuesday, 30'th Jul 2024
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients w
MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wit
Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts
01:36am, Monday, 20'th May 2024
Panbela Therapeutics, Inc. (NASDAQ:PBLA – Free Report) – Analysts at HC Wainwright dropped their Q2 2024 earnings per share estimates for Panbela Therapeutics in a research note issued to
Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript
07:30pm, Wednesday, 15'th May 2024
Panbela Therapeutics, Inc. (OTC:PBLA) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants James Carbonara - IR, HaydenIR Jennifer Simpson - President & CEO Susan Horvath - CF
Panbela Provides Business Update and Reports Q1 2024 Financial Results
04:10pm, Wednesday, 15'th May 2024
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet m
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
04:15pm, Wednesday, 01'st May 2024
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
08:00am, Tuesday, 30'th Apr 2024
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients wi
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
08:00am, Monday, 22'nd Apr 2024
Trial's lower-than-expected event rate suggests improved survival outcomes Trial's lower-than-expected event rate suggests improved survival outcomes
Panbela Announces Poster Presentation at American Association for Cancer Research:
08:00am, Thursday, 18'th Apr 2024
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models Ivospemin/doxorubicin combination modulates polyamine metabolism to improve surviva
